BPC-157 · 15 amino acids

· updated

Is BPC-157 Legal in 2026? The Honest, Current Answer


Update, Oct 30, 2026: in a notice filed Oct 28, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding BPC-157 under set conditions, including a patient-specific prescription. BPC-157 is still unapproved and still not on the 503A Bulks List. Read the HHS policy breakdown.

The short answer

As of this article’s publish date, BPC-157 is neither an FDA-approved drug nor a substance banned outright. It sits in a regulatory gray zone: it’s no longer on the FDA’s “restricted for compounding” list, but it also hasn’t been formally cleared for pharmacy compounding either. The only route that looks like a legitimate, provider-supervised path is a prescription from a licensed provider filled by a compliant compounding pharmacy — and even that path is currently under review. Here’s the actual timeline behind that answer.

Key facts

The distinction people get wrong

Headlines love to say BPC-157 is “legal now” or still “banned.” Both are oversimplified. Three separate things are in play:

In April 2026, BPC-157 came off Category 2 following the withdrawal of its restriction nomination. That removed a red flag — it did not add a green light. It’s a gray zone, not a clearance.

The dated timeline

A PCAC recommendation isn’t a final decision — FDA rules on it separately, on its own timeline, after the meeting.

So what can you actually do right now?

For the full picture of what’s being reviewed and why, see our breakdown of the July 2026 PCAC meeting, and check the live legal status tracker for the current status of BPC-157 and other peptides.

Frequently asked questions

Is BPC-157 FDA-approved?

No. BPC-157 has never gone through the FDA approval process for any use, so it is not an approved medicine.

Is BPC-157 on the 503A Bulks List now?

Not yet. The PCAC recommended it on July 23, 2026, but that vote is advisory, and the FDA still has to complete notice-and-comment rulemaking; as of October 29, 2026, it had not proposed adding BPC-157. HHS’s interim policy, filed October 28, is enforcement discretion and does not put it on the list.

No. It is not a legal over-the-counter supplement, and “research chemical” vendors operate outside a regulated, quality-controlled supply chain. The only path that resembles legitimate access is a prescription from a licensed provider filled by a licensed compounding pharmacy.

Sources

← All articles